1166 related articles for article (PubMed ID: 30253289)
1. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
[TBL] [Abstract][Full Text] [Related]
2. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
[TBL] [Abstract][Full Text] [Related]
3. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
Hsu CY; Chen LR; Chen KH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
[TBL] [Abstract][Full Text] [Related]
4. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
5. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.
Hu L; Napoletano A; Provenzano M; Garofalo C; Bini C; Comai G; La Manna G
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293076
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
[TBL] [Abstract][Full Text] [Related]
7. Osteo-renal regulation of systemic phosphate metabolism.
Razzaque MS
IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
[TBL] [Abstract][Full Text] [Related]
8. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
9. Arterial accelerated aging in dialysis patients: the clinical impact of vascular calcification.
Brancaccio D; Bellasi A; Cozzolino M; Galassi A; Gallieni M
Curr Vasc Pharmacol; 2009 Jul; 7(3):374-80. PubMed ID: 19601862
[TBL] [Abstract][Full Text] [Related]
10. Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
Cozzolino M; Galassi A; Pasho S; Fallabrino G; Gallieni M; Brancaccio D
Contrib Nephrol; 2008; 161():234-239. PubMed ID: 18451682
[TBL] [Abstract][Full Text] [Related]
11. Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children.
Bacchetta J; Bernardor J; Garnier C; Naud C; Ranchin B
Calcif Tissue Int; 2021 Jan; 108(1):116-127. PubMed ID: 31996964
[TBL] [Abstract][Full Text] [Related]
12. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
13. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
14. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
Spasovski G
Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
[TBL] [Abstract][Full Text] [Related]
15. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
16. Bone health and vascular calcification relationships in chronic kidney disease.
Spasovski GB
Int Urol Nephrol; 2007; 39(4):1209-16. PubMed ID: 17899431
[TBL] [Abstract][Full Text] [Related]
17. Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism.
McCabe KM; Zelt JG; Kaufmann M; Laverty K; Ward E; Barron H; Jones G; Adams MA; Holden RM
J Pharmacol Exp Ther; 2018 Sep; 366(3):433-445. PubMed ID: 29903718
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications.
Kaur R; Singh R
Life Sci; 2022 Dec; 311(Pt B):121148. PubMed ID: 36336124
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).
Hruska KA; Choi ET; Memon I; Davis TK; Mathew S
Pediatr Nephrol; 2010 Apr; 25(4):769-78. PubMed ID: 19898875
[TBL] [Abstract][Full Text] [Related]
20. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
